S1360
Interdisciplinary - Global health
ESTRO 2026
Results: Overall, 289 professionals from 59 countries participated. Routine use of SBRT was reported by 96.5% of respondents, with lung, bone, liver and prostate as the most frequent indications. Pancreatic tumor (48.4%), renal cell carcinoma (46.4%), and ventricular tachycardia (12.4%) represented emerging indications. C-arm linacs (89.2%) and in-room Cone beam CT (CBCT) (92.0%) were the dominant technologies. Motion management relied mainly on 4D-CT internal target volume (ITV) (88.9%) and deep inspiration breath-hold (DIBH) (57.8%). Fractionation was consistent for lung and prostate but heterogeneous for liver, and pancreas. Only 3.5% reported routine use of online adaptive SBRT, while 61.5% reported artificial intelligence (AI) use, mainly for organs-at-risk delineation. Key barriers included limited clinical trial funding (35.2%), high equipment costs (34.2%), insufficient reimbursement (27.7%), and workforce shortages (33.9%) Conclusion: This ESTRO international survey provides the first global overview of SBRT practices. It demonstrates broad adoption but also substantial variability, highlighting the need for consensus guidelines, greater trial access, and expanded education to harmonize SBRT delivery and ensure equitable care worldwide Keywords: SBRT, SABR, stereotactic body radiation therapy Digital Poster 3156 Disparities in Genitourinary Radiotherapy Access in Brazil: A Population-Based Analysis Vanessa F Bratti 1 , Silmara R Segala 2 , Daniel Del Rosso 3 , Gustavo A Viani 4 , Maria Thereza M Starling 5 , Arthur A Rosa 6 , Gustavo N Marta 7 , Ana Carolina Chamamura 4 , Samir A Hanna 7 , Cecília F.P.M. de Sousa 8 , Theodoros Tsakiridis 9 , Fabio L Cury 10 , Fabio Y Moraes 1 , Andre G Gouveia 11,12 1 Department of Oncology, Queen's University, Kingston, ON, Canada. 2 Centre for Probe Development and Commercialization, McMaster University, Hamilton, ON, Canada. 3 Public Health Sciences, McMaster University, Hamilton, ON, Canada. 4 Radiation Oncology, Hospital das Clínicas, UNESP, Botucatu, Brazil. 5 Department of Oncology, Hospital Madre Teresa, Belo Horizonte, Brazil. 6 Radiation Oncology, Hospital Santa Izabel, Salvador, Brazil. 7 Radiation Oncology, Sirio Libanes Hospital, Sao Paulo, Brazil. 8 School of Public Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, USA. 9 Department of Radiation Oncology, McMaster University, Hamilton, Canada. 10 Department of Oncology, McGill University, Motreal, QB, Canada.
The Netherlands Cancer Institute, Amsterdam, Netherlands. 6 Department of Radiation Oncology, Duesseldorf University Hospital, Duesseldorf, Germany. 7 Department of Radiotherapy, Erasmus MC Cancer Institute, Rotterdam, Netherlands. 8 Academic Department of Radiation Oncology, centre Oscar- Lambret, Lille, France. 9 Lille University, CRIStAL CNRS UMR, Lille, France. 10 Department of Radiation Oncology, Amsterdam UMC, Amsterdam, Netherlands. 11 Department of Radiation Oncology, University Medical Center Mannheim, Mannheim, Germany. 12 DKFZ-Hector Cancer Institute, University Medical Center Mannheim, Mannheim, Germany. 13 Radiation Oncology, University Hospitals Leuven, Leuven, Belgium. 14 Department of Oncology, Copenhagen University Hospital - Herlev and Gentofte, Copenhagen, Denmark. 15 Department of Radiotherapy, Medical University of Lodz, Ł ód ź , Poland. 16 Department of External Beam Radiotherapy, Copernicus Memorial Hospital in Lodz Comprehensive Cancer Center and Traumatology, Ł ód ź , Poland. 17 Department of Radiotherapy, Utrecht University and University Medical Center Utrecht, Utrecht, Netherlands. 18 University hospitals Bristol and Weston, University hospitals Bristol and Weston, Bristol, United Kingdom. 19 Radiation Oncology Department, Hospital Universitario Ramón y Caja and Biomarkers and Therapeutic Targets Group, Madrid, Spain. 20 Radiation Oncology, ARNAS Civico Hospital, Palermo, Italy. 21 Advanced Radiation Oncology Department, IRCCS Sacro Cuore Don Calabria Hospital, Verona, Italy. 22 Department of Radiology, University of Yamanashi, Yamanashi, Japan. 23 Department of Radiation Oncology, Sunnybrook Health Science Centre, Ontario, Canada. 24 Department of Radiation Oncology and Department of Neurological Surgery, University of Washington and Fred Hutchinson Cancer Center, Seattle, USA. 25 Department of Radiation Oncology, University Hospital Zurich, Zurich, Swaziland Purpose/Objective: Stereotactic Body Radiation Therapy (SBRT) has become an established treatment for several primary and metastatic malignancies; however, considerable heterogeneity remains in its definition, clinical indications, and technical delivery Material/Methods: In May 2025, the SBRT Focus Group of the European Society for Radiotherapy and Oncology (ESTRO), in collaboration with International Stereotactic Radiosurgery Society (ISRS), the Radiosurgery Society (RSS), and the Japanese Society for Radiation Oncology (JASTRO), conducted a global survey. A 44-item questionnaire explored SBRT indications, technical aspects, dose/fractionation, and barriers to implementation. Descriptive statistics summarized the responses
Made with FlippingBook - Share PDF online